A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
出版信息
Br Heart J. 1978 Oct;40(10):1069-118. doi: 10.1136/hrt.40.10.1069.
Abstract
摘要
相似文献
1
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Br Heart J. 1978 Oct;40(10):1069-118. doi: 10.1136/hrt.40.10.1069.
2
The clofibrate trial--the lipid hypothesis retested.
Med J Aust. 1979 Jun 2;1(11):490-1.
3
[Real or alleged risks of clofibrate derivatives and certain risks of their prohibition].
Nouv Presse Med. 1979 Mar 31;8(15):1223-5.
4
Cholesterol, clofibrate and ischaemic heart disease. Facts and emotions around.
Cor Vasa. 1979;21(6):377-9.
5
6
7
Cholesterol, coronaries, clofibrate and death.
N Engl J Med. 1978 Dec 14;299(24):1360-2. doi: 10.1056/NEJM197812142992409.
8
[Study of clofibrate. The opinion of Prof. D. Kritchevsky].
Minerva Cardioangiol. 1980 Nov;28(11):759-60.
9
Clofibrate and niacin in coronary heart disease.
JAMA. 1975 Jan 27;231(4):360-81.
10
Clofibrate for prevention of myocardial infarction.
Med Lett Drugs Ther. 1973 Apr 27;15(9):37-8.
引用本文的文献
1
Synthetic β-d-Glucuronides: Substrates for Exploring Glucuronide Degradation by Human Gut Bacteria.
ACS Omega. 2024 Dec 20;10(1):1419-1428. doi: 10.1021/acsomega.4c09036. eCollection 2025 Jan 14.
2
Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia.
Front Cardiovasc Med. 2024 Aug 7;11:1389106. doi: 10.3389/fcvm.2024.1389106. eCollection 2024.
3
Historical Review of the Use of Relative Risk Statistics in the Portrayal of the Purported Hazards of High LDL Cholesterol and the Benefits of Lipid-Lowering Therapy.
Cureus. 2023 May 1;15(5):e38391. doi: 10.7759/cureus.38391. eCollection 2023 May.
4
[Medicines withdrawn in other countries due to safety concerns: should they continue to be available in the Argentine pharmaceutical market?].
Rev Fac Cien Med Univ Nac Cordoba. 2022 Sep 16;79(3):241-247. doi: 10.31053/1853.0605.v79.n3.35443.
5
Dietary Transitions and Health Outcomes in Four Populations - Systematic Review.
Front Nutr. 2022 Feb 9;9:748305. doi: 10.3389/fnut.2022.748305. eCollection 2022.
6
Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer.
Pharmaceuticals (Basel). 2022 Jan 26;15(2):151. doi: 10.3390/ph15020151.
7
Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
Curr Atheroscler Rep. 2021 Oct 14;23(12):74. doi: 10.1007/s11883-021-00971-y.
8
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap.
Eur Heart J Suppl. 2020 Oct 6;22(Suppl J):J21-J33. doi: 10.1093/eurheartj/suaa116. eCollection 2020 Oct.
9
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.
Int J Mol Sci. 2019 Oct 11;20(20):5055. doi: 10.3390/ijms20205055.
10
Medical therapeutics: mortality effects, uncertainty, and informed consent.
Porto Biomed J. 2019 Feb 2;4(2):e35. doi: 10.1097/j.pbj.0000000000000035. eCollection 2019 Mar-Apr.
本文引用的文献
1
Reduction of serum-lipid and uric-acid levels by an orally active androsterone.
Lancet. 1962 Jun 23;1(7243):1321-3. doi: 10.1016/s0140-6736(62)92422-4.
2
RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE; THE FRAMINGHAM STUDY.
Ann Intern Med. 1964 Nov;61:888-99. doi: 10.7326/0003-4819-61-5-888.
3
Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate.
Lancet. 1962 Jun 23;1(7243):1323-6. doi: 10.1016/s0140-6736(62)92423-6.
4
Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate.
Nature. 1962 Jun 9;194:948-9. doi: 10.1038/194948a0.
5
The electrocardiogram in population studies. A classification system.
Circulation. 1960 Jun;21:1160-75. doi: 10.1161/01.cir.21.6.1160.
6
Estimation of the probability of an event as a function of several independent variables.
Biometrika. 1967 Jun;54(1):167-79.
7
Evaluation of survival data and two new rank order statistics arising in its consideration.
Cancer Chemother Rep. 1966 Mar;50(3):163-70.
8
Serum triglycerides in health and in ischemic heart disease.
N Engl J Med. 1965 Oct 28;273(18):947-52. doi: 10.1056/NEJM196510282731802.
9
Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.
N Engl J Med. 1967 Feb 2;276(5):273-81 concl. doi: 10.1056/NEJM196702022760507.
10
Clofibrate in coronary heart disease. Effect on morbidity and mortality.
JAMA. 1972 Feb 14;219(7):845-51.
Zotero 插件